You are here

Breakthrough Device Status for MediBeacon’s Transdermal GFR Measurement System

Device Measures GFR in Patients with Impaired, Normal Kidney Function

The FDA has designated the Transdermal Glomular Filtration Rate (TGFR) measurement system, manufactured by MediBeacon (St. Louis, Missouri), as a combination product. The TGFR device includes an optical skin sensor, a monitor, and a proprietary fluorescent tracer agent known as MB-102, which glows when light is present. The device will provide continuous real-time GFR measurement in patients with impaired or normal renal function without any need for blood sampling or urine collection.

The ability to measure GFR is critical, particularly in patients who have kidney disease or who are at risk of developing it. Kidney disease, known as a hidden epidemic, affects more than 850 million people worldwide, overshadowing the number of people who are affected by diabetes and cancer.

A press release from MediBeacon noted that tracer agents and devices from the company, including the transdermal GFR measurement system, have not been approved or cleared for human use by any regulatory agency.

Source:, October 22, 2018

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time